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Abstract
Background: The dopaminergic system is implicated in many mental processes and neuropsychiatric disorders. 
Pharmacologically, drugs with dopamine receptor antagonistic and agonistic effects are used, but their effects on functional 
brain metabolism are not well known.
Methods: In this randomized crossover, placebo-controlled, and rater-blinded study, 25 healthy adults received an acute dose 
placebo substance (starch), quetiapine (dopamine receptor antagonist), or pramipexole (dopamine agonist of the nonergoline 
class) 1 hour before the experiment. Background-suppressed 2D pseudo-continuous arterial spin labeling was used to 
examine whole-brain baseline cerebral blood flow differences induced by the 3 substances.
Results: We found that quetiapine reduced perfusion in the occipital (early visual areas) and bilateral cerebellar cortex 
relative to placebo. In contrast, quetiapine enhanced cerebral blood flow (relative to placebo) in the striatal system (putamen 
and caudate nucleus) but also in the supplementary motor area, insular-, prefrontal- as well as in the pre- and postcentral 
cortex. Pramipexole increased cerebral blood flow compared with placebo in the caudate nucleus, putamen, middle frontal, 
supplementary motor area, and brainstem (substantia nigra), but reduced cerebral blood flow in the posterior thalamus, 
cerebellum, and visual areas. Pramipexole administration resulted in stronger cerebral blood flow relative to quetiapine in 
the hypothalamus, cerebellum, and substantia nigra.
Conclusions: Our results indicate that quetiapine and pramipexole differentially modulate regional baseline cerebral blood 
flow. Both substances act on the dopaminergic system, although they affect distinct regions. Quetiapine altered dopaminergic 
function in frontal, striatal, and motor regions. In contrast, pramipexole affected cerebral blood flow of the nigrostriatal 
(striatum and substantia nigra) dopaminergic, but less the fronto-insular system.
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Introduction
The brain’s dopaminergic system has been implicated in a 
number of mental disorders, such as schizophrenia (Howes 
and Kapur, 2009) and depression (Dunlop and Nemeroff, 2007). 
Pharmacologically, dopamine (DA) receptor antagonists are pri-
marily used in the treatment of psychotic and agitated symptoms, 
whereas DA D2 receptor agonists are approved mainly for treat-
ment of Parkinson’s disease (PD) and Restless Legs Syndrome, but 
have also been used as monotherapy and augmentative treat-
ment in depression (Corrigan et al., 2000; Goldberg et al., 2004). 
Quetiapine (QT) acts as antagonist at the DA D2 receptor, as 
well as at the serotonin 2A (5-HT2A) receptor (dose-dependent, 
besides additional effects at the H1 and other 5-HT and adren-
ergic receptors). Specifically, QT is characterized by a high affin-
ity for the 5-HT2A receptor and a fast dissociation rate (and low 
affinity) for the DA D2 receptor (Kessler et al., 2006), although it 
has also been shown that QT can have a high (striatal) DA D2 
receptor occupancy in some cases (Tauscher et al., 1997; Pavics 
et al., 2004). Based on these pharmacological targets, QT is used 
to treat patients with schizophrenia, bipolar disorder, autism, and 
depression (Wen et al., 2014). In contrast, pramipexole (PX) acts as 
a selective agonist on the DA D2 and D3 receptor (Kvernmo et al., 
2006) and also shows antidepressant properties (Goldberg et al., 
2004). Pharmacologically, DA D2, D3, and D4 receptors are clus-
tered as DA D2-like receptors compared with DA D1 and D5 recep-
tors (Stoof and Kebabian, 1981; Mansour and Watson, 2000; Neves 
et al., 2002). Overall, PX and QT have relatively good pharmaco-
logically opposed mechanisms (except for the serotonergic and 
histaminergic actions of QT). Neuroanatomically, DA D2 recep-
tors are primarily found in entorhinal, orbitofrontal, and insular 
cortical areas, and subcortically in the striatum (e.g., caudatum, 
putamen, nucleus accumbens, globus pallidum, and the ventral 
striatum), the central amygdala, and the substantia nigra and 
ventral tegmental area in the midbrain (Rosenkranz and Grace, 
2002a, 2002b; Ott et al., 2014). DA D3 receptors are not found in 
neo- and palleocortical areas and the orbitofrontal region but are 
strongly represented in the nucleus accumbens shell and specifi-
cally the Islands of Calleja (Ridray et al., 1998). In schizophrenia, 
there is an ongoing debate whether functional and structural 
brain changes seen in patients are due to the disorder itself, 
an effect of antipsychotic treatment, or a combination of both 
(e.g., recent meta-analyses: Fusar-Poli et al., 2013; Haijma et al., 
2013; Vita et al., 2015). Antipsychotic pharmacological effects are 
thought to rely primarily on DA receptor antagonistic effects. 
However, despite the known distribution of the receptors in the 
brain, the main places of action of dopaminergic drugs are not 
well characterized. A  recent meta-analysis on pharmacological 
functional magnetic resonance imaging (phMRI) studies summa-
rized the evidence for acute and chronic effects of antipsychotics 
(including QT) on the fMRI signal in cortical and also striatal and 
nigrostriatal regions (Roeder et al., 2013). For example, treatment 
with QT in healthy participants for 3 days increased functional 
connectivity of anterior cingulate cortex (ACC) and dorsolateral 
prefrontal cortex with the amygdala during a virtual aggressive 
behavior task (Klasen et al., 2013). QT has been shown to increase 
the fMRI signal of the orbitofrontal lobe during emotional (Fahim 
et al., 2005; Stip et al., 2005; Mancini-Marie et al., 2006) and verbal 
fluency task processing (Jones et al., 2004) in patients with schizo-
phrenia and one case report in depersonalization disorder treated 
for a period of several weeks.
DA agonists have been shown to increase prefrontal perfu-
sion in rats (Nordquist et al., 2008) and in humans with schizo-
phrenia (Mu et al., 2007).
One method to characterize basic pharmacological effects in 
the brain is (pseudo-continuous) arterial spin labeling (pCASL) 
MRI, which measures noninvasively cerebral blood flow (CBF) 
variations. Changes in CBF can not only be affected by localized 
brain activity, but also possibly by vascular effects due to dopa-
minergic and other receptors on glial cells and cerebral vascula-
ture (Mandeville et al., 2013). In addition, changes in CBF can also 
be affected by pharmacological effects on the coupling between 
brain metabolism and the vascular reaction. We would expect 
such vascular effects of dopaminergic modulation to be rather 
homogeneously distributed, reflecting a direct vasodilatory effect 
on cerebral blood vessels, as observed for levodopa (Leenders 
et al., 1985) or DA per se (Sabatini et al., 1991; Krimer et al., 1998). 
One previous ASL study showed decrements in CBF in the pre-
frontal cortex (PFC) after 7-day treatment with amisulpride, an 
antagonist at D2/D3 receptors (Viviani et  al., 2013). The acute 
application of amphetamines, however, which block the reuptake 
and thereby increase the levels of DA, lowers CBF in the nigrostri-
atal but not in the cortical system (Lavyne et al., 1977). This reduc-
tion was similar to the effect of increased endogenous DA release 
due to stimulation of the substantia nigra (Lavyne et al., 1977). 
A recent study using pulsed continuous ASL demonstrated acute 
effects of D2 antagonist and agonist on (resting) CBF in humans 
(Handley et al., 2013). Specifically, the authors reported increased 
CBF in the basal ganglia (putamen) after a single dose of haloperi-
dol (D2 antagonist) and aripiprazole (D2 partial agonist). The CBF 
increase was more pronounced for haloperidol than for aripipra-
zole in the (right) putamen and in the striatum.
In parallel to amphetamines, PX decreased regional CBF, 
measured using Positron Emission Tomography (PET) in 
baboons, in orbital frontal cortex, thalamus, cingulated cortex, 
and insula, whereas it increased relative CBF was shown in the 
temporal poles, cerebellum, and visual cortex (Black et al., 2002).
In the current study, we aimed to characterize acute effects 
of dopaminergic agonistic and antagonistic modulation on CBF 
at rest to enable conclusions about the site of action under 
acute administration of dopaminergic drugs. We used pCASL in 
healthy adults to identify CBF changes after acute application 
of QT and PX compared with placebo. In a randomized way, all 
subjects were supplied (at 3 different days, each at least 1 week 
apart, similar day-times) with one of the following substances: 
QT, PX, or placebo, and underwent every time the identical MR 
scan protocol.
Based on the known specific and spatially widespread modu-
latory effects of QT and PX on DA D2 and D3 function, we hypoth-
esize opposing effects of these drugs on CBF in the fronto-striatal 
and nigrostriatal system. Specifically, and based on previous 
reports (Handley et al., 2013), we expected to see increased CBF 
in the basal ganglia for QT and PX relative to placebo.
Methods
Participants
The sample consisted of 25 healthy volunteers (mean age: 
27.6  years ± 7.6  years, and range: 20–46  years; 13 females), 
although reliable pCASL could be achieved in only 23 subjects. 
All participants in this sample were right-handed (Annett, 
1967). Exclusion criteria included any kind of metal implants 
or pacemakers; any history of medical disorders that pose risk 
to subjects (e.g., any allergy against medication; any acute or 
chronic somatic disorder [particularly affecting cardiac and vas-
cular function]; pulmonary disease, neurological, psychiatric, 
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haematological, endocrine, or major genitourinary disease) or 
jeopardize the aim of the study by introducing confounds (e.g., 
prevalence of illicit drug usage, daily consumption of more than 
2 alcoholic beverages, intensive cigarette smoking [>1 pack/d)] 
and heavy caffeine consumption). Participants were screened 
for current and previous mental disorders using the MINI inter-
view (Sheehan et al., 1998).
The study protocol was approved by the institutional review 
board of the County of Zurich, Switzerland (KEK no. ZH-2009-0060) 
and was conducted in accordance with the Declaration of Helsinki. 
All participants provided written informed consent after full expla-
nation of the procedures and received monetary compensation.
Drug Treatment
Each participant received 1 to 1.5 hours before each of the 3 
scans a single dose of 100 mg QT, 0.5mg PX, or placebo (starch 
tablet without any pharmacologically active ingredient, identi-
cal to the QT and PX tablets in size and color). The drugs were 
administered in a closed wrap. The dosages were chosen to 
avoid strong side effects such as hypotension and sedation (QT) 
and nausea (PX). The drugs were administered in a single-blind, 
randomized, crossover design. We do use the term “treatment” 
here for this single-dose design, but it should not be confused 
with longer term treatment protocols.
Acquisition of Structural Data
MR scans were acquired on a 3T Philips Achieva scanner (Philips 
Healthcare, Best, The Netherlands) equipped with an 8-chan-
nel head coil. MR-compatible headphones were used to mini-
mize head motion. A  T1-weighted 3D-MPRAGE anatomical 
scan was recorded with the following parameters: time of rep-
etition/time of echo: 8.3/3.8 ms, flip angle: 8°, voxel resolution: 
0.94 × 0.94 × 1 mm, field of view: 240 mm, and 160 slices.
ASL Acquisition
CBF was measured with a 2D background-suppressed pseudo-
continuous ASL (pCASL) sequence (Wong et al., 1997). PCASL was 
chosen because of its high signal-to-noise characteristics (Wu 
et al., 2007; Dai et al., 2008). The acquisition parameters were: time 
of repetition/time of echo: 4120/15 ms, flip angle: 90°, field of view: 
240 mm, number of slices: 23, number of dynamics: 35, in plane res-
olution: 3 x 3, thickness: 7 mm (no gap), labeling time: 1.65 seconds, 
postlabeling delay: 1.525 seconds, and scan duration: 4:56 minutes. 
Two background suppression pulses (at 1.68 and 2.76 seconds) were 
used. M0 are the equilibrium brain tissue magnetization images 
(Wang et al., 2003a; Federspiel et al., 2006; Jann et al., 2010) and were 
recorded in a separate run for each participant immediately after 
the pCASL scan using the same parameters as described for the 
pCASL sequence apart from the time of repetition (10 000 ms).
ASL Analysis
ASL images were preprocessed using the toolbox “ASLtbx” (Wang 
et al., 2008), which was compatible with MATLAB and the SPM 
software package (http://www.fil.ion.ucl.ac.uk/spm/), used for 
group comparison analysis. The first step was motion correction 
(Wang, 2012) and denoising. Subjects were excluded from subse-
quent analysis if any of the 3 (scan-to-scan) translation param-
eters exceeded one-half of the voxel size or if rotation values 
exceeded 1° (which was the case in 2 participants). This step was 
also important to minimize global signal outliers (spikes) dur-
ing the calculation of perfusion signal by pairwise subtraction, 
resulting from inconsistent background suppression or spatial 
location offset due to head motion. Next, we performed denois-
ing, which included spatial smoothing with an isotropic Gaussian 
at full-width-at-half-maximum of 6 mm3 to reduce interindi-
vidual anatomical differences and further increase the signal-
to-noise ratio. Then, all nonbrain voxels were excluded using 
the Freesurfer software (relevant functions: ‘fslmerge’ to create a 
mean brain mask and ‘fslstats’ to remove nonbrain voxels).
As a next step, CBF quantification was performed using a sin-
gle compartment model (Buxton et al., 1998; Wang et al., 2008), 
and its estimation is explained in the next paragraph. For the 
calculation of the perfusion difference images (Mcontrol – Mlabel), 
simple pairwise subtraction (label – control) was used, as it has 
been demonstrated to efficiently minimize spurious BOLD con-
taminations within the CBF signal (Wang et al., 2003b; Liu and 
Wong, 2005). Furthermore, it has been demonstrated that sim-
ple subtraction in resting-state CBF data works with the same 
performance as special filtering approaches (Liu and Wong, 
2005; Chuang et al., 2008). During CBF quantification, volunteer’s 
mean CBF maps were corrected for the (tissue-dependent) pro-
ton density derived from the M0 image.
CBF Quantification
CBF was calculated on a voxel-wise basis according to the 
formula: 
CBF 
60 * 100* control=
* -( )
-
- -
λ
α
M M
T M e e
label
blood
w
T blood2 1 0 1*
w
T blood
+æ
è
ççççç
ö
ø
÷÷÷÷÷
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1
Mcontrol − Mlabel reflects the subtraction of label and control 
images, and λ = blood brain partition coefficient for water = 0.9 
(Herscovitch and Raichle, 1985), T1blood = 1664 ms (Lu et al., 2004), 
M0 = equilibrium brain tissue magnetization images, τ = labeling 
pulse train length = 1.68 s, α = labeling efficiency = 0.85 (Dai et al., 
2008), as background suppression was used, and w (posttagging 
delay) = 1.53 s.
The labeling efficiency and the T1 of blood were taken from 
literature values, derived from previous experimental studies 
(Lu et al., 2004; Dai et al., 2008), and were part of the compart-
ment model (see above) or entered as variables in the ASLtbx, 
respectively. The equilibrium magnetization of blood was calcu-
lated from the equilibrium magnetization of CSF and multiplied 
by a correction factor for T2* decay. The relevant blood H2O parti-
tion coefficient was taken from the literature (Herscovitch and 
Raichle, 1985).
After CBF quantification, volunteers’ mean CBF map were 
normalized to the Montreal Neurological Image (MNI) template 
(average of 200 realigned brain images) to allow for statistical 
treatment comparisons (see below). The MNI template was pro-
vided by the SPM8.
Global CBF Calculation
First, a brain mask template was created for each subject to 
exclude all nonbrain voxels from the normalized CBF map 
(using the FSL software package, http://fsl.fmrib.ox.ac.uk/fsl/
fslwiki/). Then, a mean whole-brain CBF map (i.e., uncorrected 
for partial volume effects) was calculated by averaging all voxels 
across all subjects. This map was used to show CBF variations 
across the whole brain for the different treatments (placebo, 
QT, and PX) on the group level. In addition, we used individuals’ 
global CBF values as confounding covariate at the voxelwise CBF 
analysis (see below).
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Figure 1. Whole-brain cerebral blood flow (CBF) maps for the 3 treatment groups: placebo (top), quetiapine (middle), and pramipexole (bottom). Lighter areas represent 
areas with higher CBF. CBF maps are shown on axial slices: range z = -22 to z = 44 (gap: 10 mm) and are given in mL/100 g/min. The CBF maps reveal the absence of any 
strong lateralization effects in the anterior-posterior, inferior-superior, or left-right direction.
Whole-Brain CBF Statistical Analysis
A general linear model (GLM), in our case a repeated-meas-
ures ANOVA, was applied using SPM8 to assess whole-brain 
CBF effects on the voxel-to-voxel level. CBF differences were 
estimated for 3 contrasts: “placebo – QT” (and reversed), 
 “placebo – PX” (and reversed), and “QT – PX” (and reversed). First, 
we tested with for a main effect of treatment (placebo, QT, and 
PX). Next, we applied posthoc t tests to assess between-treat-
ment effects. Whole-brain CBF differences are reported using a 
voxel-wise threshold of P < .001 (t > 3.2, uncorrected) or, for visu-
alization purposes, P < .005 (t > 2.66, uncorrected). Only clusters 
>10 voxels (>0.63 mL) are shown. Additionally, we performed the 
same type of analysis, but this time we included individuals’ 
global CBF values as confounding covariate in the GLM. For cor-
tical regions, CBF values are reported with corresponding ana-
tomical names and Brodmann areas (BAs).
We also estimated the local CBF change for QT and PX rela-
tive to placebo, in regions showing the strongest difference, 
estimated as follows: (CBF QT [or PX] – CBF placebo)/CBF pla-
cebo) *100 (to gain relative CBF changes in percent). To assess a 
global estimate of percent CBF differences, regions of interest 
(ROIs) were created using ROIs from the Automated Anatomical 
Labeling atlas (Tzourio-Mazoyer et  al., 2002), which hence 
included the local peak CBF between-treatment difference but 
also some surrounding intra-regional volume. Since it is known 
that particularly CBF in the basal ganglia is altered after treat-
ment with D2 antagonists or agonists (Handley et al., 2013), we 
extended the ROI analysis to these regions, including the (right 
and left) putamen, caudate nucleus, and pallidum.
Finally, we tested whether voxelwise CBF treatment differ-
ences are the by-product of intra-treatment time-dependent CBF 
changes. Here we first estimated within-treatment CBF maps for 
the first and second halves of the recording and then compared 
(by paired t tests) those sets of CBF maps. All statistical maps were 
examined on a rather exploratory statistical threshold of P < .01 
(uncorrected) to not miss any drug-induced temporal CBF change.
Acquisition of Physiological Data
We recorded blood pressure and heart rate (beats per minute) 
before and after each pCASL scan. Additionally, we tested whether 
between-treatment differences remained stable if we included 
the blood pressure ratio (ratio systolic/diastolic value), mean arte-
rial pressure (MAP), or heart rate as regressor of no interest in the 
GLM. The MAP was calculated according to MAP = 2/3 diastolic + 1/3 
systolic value. The GLM was calculated separately for the effect of 
cardiac parameters using pre- and post-ASL scan values.
Results
Whole-Brain Analysis
Across all 3 treatments, whole-brain analysis revealed a main 
effect of treatment (F = 7.8, P < .001) with significant clusters in 
the right visual cortex (MNI x/y/z: 6/-80/12), left brain stem (MNI: 
-10/-10/-10), left prefrontal cortex (MNI: -40/54/20), and right cer-
ebellum (MNI: 31/-64/-38). Global CBF maps for each treatment 
are shown in Figure 1, indicating (a) high-quality ASL recordings 
for all 3 treatments, and (b) the absence of any strong laterali-
zation effects in the anterior-posterior, inferior-superior, or left-
right direction.
As shown in Figure  2 and Table  1, the between treatment 
comparison revealed the following:
 by guest on Septem
ber 1, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Michels et al. | 5
• QT reduced CBF relative to placebo, particularly pronounced 
in the bilateral visual cortex (19.05% CBF change), but also 
in the bilateral cerebellum (Crus 2) with a right hemispheric 
dominance.
• PX reduced CBF in the right cerebellum, thalamus, and fusi-
form cortex relative to placebo. If global CBF was included 
as confounding variable in the analysis, we found further 
decreases in CBF in the left fusiform gyrus, right cuneus, and 
superior temporal gyrus (global CBF was not significantly dif-
ferent between the treatments, all P > .5).
• QT increased perfusion relative to placebo in the left middle 
and right superior prefrontal cortex and left caudate nucleus 
and at the border of left posterior part of the putamen and 
insular cortex (4% CBF change). If global CBF was included 
in the GLM, CBF was increased in left the pre- and postcen-
tral gyri, bilateral inferior frontal orbital gyrus, right caudate 
nucleus, and right SMA.
• No CBF increases were detected when comparing QT with PX 
at P < .001 or P < .005.
• PX increased CBF relative to placebo in the bilateral caudate 
nuclei, left brainstem (including substantia nigra, 7% CBF 
change), and the left SMA and middle frontal gyrus (BA 11) if 
global CBF was included in the GLM.
• PX showed elevated CBF compared with QT in the left cer-
ebellum and brainstem (including substantia nigra, 8% CBF 
change) and right hypothalamus.
Figure 2. Statistical between-treatment cerebral blood flow (CBF) comparisons. All comparisons (placebo vs quetiapine [QT], QT vs placebo, placebo vs pramipexole 
[PX], PX vs placebo, and PX vs QT) are shown at a voxel-threshold P < .005 (uncorrected). Areas in blue denote changes in CBF with global CBF as confounding covariate 
in the statistical model. Areas in red indicate changes in CBF without global CBF as confounding variable in the analysis. Areas in pink show the spatial overlap between 
the 2 analyses. See Table 1 for the complete list of all significant CBF changes.
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Table 1. Treatment-Related CBF Differences
Contrast
Region
(with Hemisphere)
L: left, R: right
MNI Coordinates
x/y/z BA t-Value Cluster size
PX > QT
Cerebellum L (Crus 2) -37 / -68 / -40 2.86 55
Brainstem L
 (substantia nigra)
-7 / -12 / -12 2.82 35
b Hypothalamus R 4 / -7 / -12 3.2 23
QT > PX No significant clusters
Placebo> QT
Lingual gyrus L -8 / -83 / -10 BA 18 3.26* 119
Calcarine gyrus R 6 / -80 / 13 BA 17/23 3.96* 243
Cerebellum L (Crus 2) -34 / -73 / -44 3.68* 37
Cerebellum R (Crus 1) 32 / -66 / -42 4.15* 249
placebo> PX
Cerebellum R (Crus 2) 24 / -78 / -43 3.07 144
Fusiform gyrus R 40 / -66 / -18 BA 19 2.91 88
b Fusiform gyrus L -35 / -78 / -16 2.7 43
Thalamus L
 (medial dorsal nucleus)
-2 / -22 / 5 2.67 74
b Cuneus R 6 / -94 /12 2.79 23
b Superior temporal gyrus R 71 / -26 / 13 2.74 33
QT > placebo
Middle frontal gyrus L -42 / 54 / 16 BA10 3.84* 116
Superior frontal gyrus R 47 / 35 / 40 BA 9 3.36* 23
b Postcentral gyrus L -30 / -38 / 50 BA 40 2.95 43
b Precentral gyrus L -24 / -10 /65 BA 6 2.92 27
Insula L -38 / 3 / -2 BA 13 2.69 158a
Insula L -37 / -14 / -3 2.99 158a
b Inferior frontal orbital R 24 / 12 / -22 BA 47 2.95 33
Inferior frontal orbital L -31 / 14 / -20 BA 47 2.96 122
Caudate L -11 / 12 / -9 2.97 27
b Caudate R 11 / 15 / 15 2.86 24
Putamen L -30 / -16 / -4 2.8 66
b Putamen L -12 / 12 / -7 2.94 49
b Supplementary motor area (SMA) R 4 / 25 / 58 BA 8 2.98 49
PX > placebo
Caudate R 20 / 21 / 12 3.30* 33
Caudate L -9 / 15 / 12 2.55 14
b Putamen L -22/ 6 / -10 2.86 36
b Middle cingulum L -5 / 6 / 44 BA 32 2.87 24
b Middle frontal gyrus L -22 / 60 / -11 BA 11 2.8 15
Brainstem L (substantia nigra) -8 / -13 / -13 3.83* 29
Abbreviations: BA, Brodmann area; PX, pramipexole; QT, quetiapine.
Significance is reported at *P < .001 (t > 3.2) and P < .005 (t > 2.66).
a Peaks within the same cluster.
b Additional significant regions when including global CBF as confounding variable.
Figure  3 shows that pre- and post-pCASL scan differences 
were mostly comparable with respect to blood pressure (ratio 
systolic/diastolic) and heart rate. Differences were seen in 
(pre and post ASL scan) heart rate comparing placebo with 
QT (pre-pCASL: P = .014; post-pCASL: P = .038), with higher 
heart rates for QT. Further, placebo-related heart rate was 
lower before pCASL than after the pCASL scan (P = .037), which 
might be a result of getting up after lying down for 1.5 hours. 
Hence, we tested whether heart rate, blood pressure (ratio), or 
MAP had relevant effects on the observed between-treatment 
differences described above (and visualized in Figure  2 and 
Table 1). However, even at a very liberal statistical threshold 
of P < .01 (uncorrected), no CBF differences were seen when 
comparing the treatment-specific GLM excluding or including 
either heart rate, MAP, or blood pressure (ratio) as regressors 
of no interest.
ROI Analysis
The ROI analysis (of the basal ganglia) demonstrated stronger 
CBF in the bilateral caudate nucleus and putamen (left-domi-
nant) as well as in the left pallidum with both treatments relative 
to placebo (Figure 4, changes are indicated in %). Some of these 
increases were significant: QT vs placebo (left caudate nucleus: 
P = .01, t = 2.67; left putamen: P = .02, t = 2.4) and PX vs placebo (left 
putamen: P = .04, t = 2.1; left pallidum: P = .1, t = 1.7). Further, the 
CBF change in the left caudate nucleus was stronger (trend) for 
the contrast QT vs placebo than for PX vs placebo (P = .07, t = 1.9).
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Figure  3. Cardiac response (blood pressure [ratio systolic/diastolic] and heart 
rate) before and after the (pseudo-continuous) arterial spin labeling (pCASL) 
scan. Between-treatment differences were mostly comparable for both time 
points. Yet, differences were seen in (pre- and post-ASL scan) heart rate compar-
ing placebo with quetiapine (QT) (pre-pCASL: P = .014; post-pCASL: P = .038), with 
higher heart rates for QT.
Discussion
Main Findings
We found that a single acute application of both DA agonists 
and antagonists altered CBF (relative to placebo) in healthy 
adults in a localized manner. Specifically, QT increased prefron-
tal (including the basal ganglia) but reduced visuo-cerebellar 
CBF compared with placebo. In contrast, PX enhanced CBF in 
the nigrostriatal (brainstem at the level of the substantia nigra 
and caudate nucleus) system but reduced CBF in the thalamus, 
visual cortex, and cerebellum.
phMRI: The Value of ASL
The 2 primary methods in phMRI include BOLD contrast 
and ASL-MRI. Although the BOLD contrast has been widely 
used in phMRI studies (Abler et  al., 2007, 2011, 2013; Bruhl 
et  al., 2010, 2011; Rawlings et  al., 2010), it has some weak-
nesses (no absolute quantification). In contrast, ASL-MRI has 
some advantages such as absolute quantification of CBF both 
at rest and during task activation and high reproducibility 
over minutes to weeks (Chen et al., 2011; Wang et al., 2011). 
Therefore, ASL can be an additional or even alternative tool 
for studying both i.v. and oral acute and longer term drug 
action as well as understanding drug effects on baseline 
brain function.
QT Effects on CBF
We found reduced CBF after QT intake in the early (calcarine and 
lingual) visual cortex and cerebellum (Crus 2) relative to placebo. 
In addition, we observed enhanced perfusion after QT in the left 
striatum (posterior putamen) and insular cortex as well as in 
other frontal regions such as the caudate nucleus, middle frontal 
gyrus (BA 10), and superior frontal gyrus (close to BA 11). However, 
we found no CBF differences in the ACC even at a liberal voxel 
Figure 4. Region of interest (ROI) analysis. Percent change in cerebral blood flow (CBF) (% with standard error) is given for 2 contrasts: quetiapine (QT) vs placebo and 
pramipexole (PX) vs placebo. The analysis was performed in anatomically defined regions of the basal ganglia, including the (left and right) caudate nucleus, putamen, 
and pallidum. Significant differences due to medication (relative to placebo) and between medications are indicated by *P < .1 or **P < .05. Apart from the right pallidum, 
both medications increased CBF (i.e., positive % change) compared with placebo.
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threshold of P < .005 (uncorrected). QT acts primarily as an antago-
nist at the DA D2 receptor but is also an antagonist on 5HT2A, 
5HT1A (partial), and H1 histaminergic receptors. DA D2 receptors 
have a high density in the mesolimbic and nigrostriatal system 
(Camps et al., 1989), whereas DA D1-receptors are mainly present 
in the cerebral cortex and cerebellum (De Keyser et  al., 1988a, 
1988b; Mansour and Watson, 2000). The nigrostriatal pathway 
includes the brainstem (clustered in the substantia nigra), ACC, 
caudate nucleus, and medial PFC. Previous PhMRI studies using 
ASL perfusion MRI have been conducted after application of the 
D2 receptor antagonist metoclopramide (Fernandez-Seara et al., 
2011). In a placebo-controlled study in healthy volunteers, a single 
oral dose of metoclopramide increased CBF bilaterally in the stria-
tum (putamen), consistent with its DA D2 receptor antagonism, 
and reduced CBF in the insular cortices and anterior temporal 
lobes. In our study, we found for the DA D2 receptor antagonist 
that QT increased CBF compared with placebo in the (posterior) 
putamen and caudate nucleus but increased in the insular cor-
tex. One reasonable explanation for this finding might be that QT 
acts differently on the DA D2 receptors than metoclopramide, as 
both substances have a differential receptor profile (additional 
M1 acetylcholine receptor agonistic effect in metoclopramide). 
The antagonistic effect of QT on 5HT2A, 5HT1 (partial), and H1 
histaminergic receptors (all present in the insular cortex; http://
human.brain-map.org/) could explain this difference, which is 
also supported by the lack of a strong effect of PX in this region.
Dopaminergic reward signals have been shown to modu-
late the BOLD signal in the visual cortex, that is, gating sensory 
plasticity (Arsenault et al., 2013). We suggest that the impact of 
QT on prefronto-striatal DA receptor function (enhanced CBF) 
is paralleled by reduced CBF in the occipital cortex, maybe as 
a result of lower control mechanisms of the PFC. The occipi-
tal cortex contains both 5HT 1A and 2A receptors (Allen Brain 
Atlas, http://www.brain-map.org), which could suggest a direct 
serotonergic effect of QT in these regions. However, we found 
similar effects in the occipital cortex after PX administration 
(see below), which rather supports a dopaminergic modulatory 
effect of QT on the occipital cortex. Another explanation for the 
reduction of CBF in the visual cortex might be the effect of QT on 
vigilance, potentially mediated by the antihistaminergic effect 
of QT. Yet this is less likely, as neither blood pressure nor heart 
rate was lower after QT relative to placebo intake (Figure 3).
The increased CBF in the motor cortex (SMA and precen-
tral gyrus) after treatment with QT in our study corresponds to 
another study in healthy individuals (Handley et al., 2013) and in 
patients using haloperidol (Lahti et al., 2009), which would sup-
port a particular D2 receptor antagonism effect in this region.
Effects of PX on CBF
Pharmacologically, PX acts specifically on DA D2 receptors. PX 
reduced in our study occipital and thalamic CBF, and we noticed 
a consistent (PX > placebo and PX > QT) increase of perfusion in 
the brainstem, specifically in the substantia nigra. This suggests 
that PX affects predominantly the nigrostriatal system com-
pared with the more cortico-striatal effects seen with QT.
In rodents, a prior study investigated DA D2 effects using 
aripiprazole, an antipsychotic, acting as DA D2 receptor par-
tial agonist. Using CASL, the study reported a dose-dependent 
decrease in brain perfusion in the entorhinal piriform and per-
irhinal cortex, nucleus accumbens shell, and basolateral amyg-
dala (Nordquist et al., 2008). Our results with PX show a different 
modulation pattern in the brain focused on the nigrostriatal and 
the limbic network.
The major afferent innervation of the basal ganglia is derived 
from the cortex and thalamus (Kemp and Powell, 1971a, 1971b). 
In our study, PX reduced CBF in thalamus relative to placebo. 
This region heavily connects to the striatum and other parts of 
the basal ganglia (McFarland and Haber, 2002). Specifically, these 
excitatory inputs from the thalamus mainly target the striatum, 
where they innervate the principal type of striatal neuron and 
are critical in the expression of basal ganglia function (Huerta-
Ocampo et  al., 2014). In schizophrenia patients, high levels of 
DA have been reported in the thalamus (Oke et al., 1988), and 
since then it has been discussed whether this area is critical 
to the pathophysiology of schizophrenia (Moghaddam, 2010). 
Indeed, our data lend support for a common but anticorrelated 
modulatory effect of PX on CBF within the thalamo-nigrostriatal 
(brainstem) system. This suggests that antipsychotic drugs (at 
least with DA agonism) can modulate CBF as they might modu-
late dopaminergic function. Interestingly, aripiprazole, which 
is a partial D2 agonist/antagonist, had no modulatory effect on 
CBF in the thalamus in a recent ASL study in healthy individuals 
(Handley et  al., 2013). This discrepancy between the 2 studies 
could be due to the partial antagonistic effect of aripiprazole.
In addition to a D2 receptor-mediated effect, PX has also 
been shown to decrease intracellular DA contents, potentially 
mediated by effects on PX production and the vesicular DA 
uptake (Izumi et al., 2008). In our study, the acute oral applica-
tion of PX resulted in a CBF increase in the midbrain (substantia 
nigra), which is consistent with its clinical use in PD (review in 
Fox et al., 2011) and other disorders involving the nigrostriatal 
motor system (e.g., tremor severity in Holmes’ tremor; Seidel 
et al., 2009) in humans and in normalizing cellular and motor 
dysfunctions in PD-affected rats (Jeon et  al., 2007; Shin et  al., 
2009). Our analyses point towards a modulatory role of QT and 
PX on the striatal system. Yet, effects turned out to be more 
widespread when we considered global CBF as a covariate of 
interest in the statistical analysis (Figure 2; Table 1). This obser-
vation is in line with a recent study (using pulsed continuous 
ASL) in healthy volunteers, who found fewer CBF changes (after 
treatment with antipsychotic drugs) when global CBF was not 
included as a covariate (Handley et al., 2013). Since global CBF 
did not differ among the selected treatment regimes, this result 
indicates that (without its inclusion) small inter-subject physi-
ological CBF differences may have hampered the identification 
of region-specific at the whole-brain (group) level.
Limitations
Our study has some limitations. The main limitation is that we 
had to use rather low dosages of both drugs to avoid side effects 
such as nausea (PX) and sleepiness/sedation (QT), which both 
would have interfered with the testing. For PX, we would not 
expect any major differences in terms of receptor occupancy 
when using higher dosages. For QT, however, some studies show 
a more prominent 5HT as well as noradrenergic receptor affinity 
in lower dosages and a stronger dopaminergic effect in higher 
dosages, but binding studies show a comparable affinity for D2 
and 5HT2A receptors (Richelson, 1999; Nemeroff et  al., 2002). 
One PET binding study showed relevant DA D2 receptor occu-
pancy even at low plasma levels in healthy controls (Nord et al., 
2011), and 2 other PET studies suggest that possibly both the DA 
D2 and the 5HT2A receptor occupancy increase with increas-
ing dose of QT (Kapur et al., 2000; Gefvert et al., 2001). However, 
other treatment studies show both a prominent cortical bind-
ing to 5HT2A receptors (Rasmussen et al., 2011) and a predomi-
nant striatal binding to dopaminergic receptors (Pavics et  al., 
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2004) even at rather low therapeutic doses. Thus, we cannot be 
absolutely certain about the pharmacological specificity of the 
QT effects alone. Yet, when combining the QT DA-antagonistic 
results with the more specific PX DA-agonistic results, we can 
draw more certain conclusions about DA-specific effects. One 
other limitation is that we have no individual plasma level 
measurements, which could explain some lack of sensitivity 
of our study; when controlling for interindividual plasma level 
differences, we could have achieved more information about 
plasma level dependent variation. Due to the possibly vary-
ing receptor profile depending on the single dosage and with 
repeated dosages, future studies might want to look at dose-
dependent effects of QT on CBF, possibly in addition measuring 
plasma levels to correlate with the CBF variation. In addition, we 
did not record baseline ASL prior to any treatment. Therefore, we 
cannot exclude any placebo effects on CBF. However, the placebo 
effect on CBF should not be locally uniform and specific across 
participants, and the direct contrast between PX and QT should 
control for potential placebo effects on regional CBF.
One important aspect, although not a limitation, is that this 
study cannot be directly compared with studies investigating 
the effect of longer term treatment in patients or healthy sub-
jects, because these longer term intake studies are measuring 
direct pharmacological and more indirect adaptive effects due 
to the treatment.
Conclusion
Our results indicate that the main regions where CBF was dif-
ferentially modulated by QT and PX, suggesting rather specific 
dopaminergic effects, were substantia nigra, cerebellum, and 
hypothalamus. Other regions such as prefrontal and subcorti-
cal areas showed elevated CBF after intake of both QT and PX, 
although with a more prominent effect of QT on prefronto-striatal 
network compared with a midbrain-striatal network modulated 
by PX. This suggests on the one hand certain specific dopamin-
ergic effects of QT, but also differences compared with other DA 
receptor antagonist (e.g., metoclopramide) and DA D2 agonists 
(e.g., PX), possibly as a result of different receptor profiles.
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